Review: Saccharomyces boulardii reduces risk for antibiotic-associated diarrhea

March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p45
Academic Journal
This article presents a study which reveals that Saccharomyces boulardii reduces risk for antibiotic-associated diarrhea. Randomized controlled trials (RCTs) were conducted which compared S. boulardii with placebo or no additional intervention in adults and children who received antibiotics for any reason. Quality assessment of individual studies included allocation concealment, blinding, intention-to-treat analysis, and comprehensive follow-up. 5 RCTs met the selection criteria. Meta-analysis was done using a random-effects model. The incidence of antibiotic-associated diarrhea was lower in the S. boulardii group than in the placebo group.


Related Articles

  • A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. Drakoularakou, A.; Tzortzis, G.; Rastall, R. A.; Gibson, G. R. // European Journal of Clinical Nutrition;Feb2010, Vol. 64 Issue 2, p146 

    Background/Objectives:Prebiotics have attracted interest for their ability to positively affect the colonic microbiota composition, thus increasing resistance to infection and diarrhoeal disease. This study assessed the effectiveness of a prebiotic galacto-oligosaccharide mixture (B-GOS) on the...

  • Is the exclusion of children under 24 months from anthelmintic treatment justifiable? Montresor, Antonio; Stoltzfus, Rebecca J.; Albonico, Marco; Tielsch, James M.; Rice, Amy L.; Chwaya, Hababu M.; Savioli, Lorenzo // Transactions of the Royal Society of Tropical Medicine & Hygiene;Mar2002, Vol. 96 Issue 2, p197 

    There are no reports documenting toxicity or adverse effects after treatment of children aged < 24 months with benzimidazole derivatives and there is an urgent need to clarify this point in light of the potential detrimental effect that soil-transmitted helminthiasis has on this age-group. A...

  • COMMENTARY: Review: Saccharomyces boulardii reduces risk for antibiotic-associated diarrhea. Parrino, Thomas A. // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p45 

    This article reports that saccharomyces boulardii reduces risk for antibiotic-associated diarrhea. Antibiotic-associated diarrhea (AAD) occurs in up to 30% of patients receiving antibiotics. The most serious form of AAD is mediated by Clostridium difficile associated diarrhea (CDAD). Several...

  • AFTER ANTIBIOTICS.  // Prevention;Feb89, Vol. 41 Issue 2, p12 

    Reports on the use of the yeast Saccharomyces boulardii to stop stubborn diarrhea in people who have been treated with wide-spectrum or multiple antibiotics. Elimination of beneficial intestinal bacteria by antibiotics; Popularity of the yeast as a prescription drug in Europe; Absorption of...

  • Bismuth Subsalicylate in the Treatment of Chronic Diarrhea of Childhood. Gryboski, Joyce D.; Hillemeier, Craig; Grill, Bruce; Kocoshis, Samuel // American Journal of Gastroenterology;Nov1985, Vol. 80 Issue 11, p871 

    Twenty-nine infants and children, age 2-70 months with chronic diarrhea, were admitted to a double-blind, parallel clinical trial. The subjects were randomly assigned to receive either a bismuth subsalicylate liquid or a placebo liquid formulation. Treatment was given for 7 days with dosage...

  • Risk Factors for Extended Duration of Acute Diarrhea in Young Children. Strand, Tor A.; Sharma, Pushpa R.; Gjessing, HÃ¥kon K.; Ulak, Manjeswori; Chandyo, Ram K.; Adhikari, Ramesh K.; Sommerfelt, Halvor // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Objective and Background: We sought to identify predictors of extended duration of diarrhea in young children, which contributes substantially to the nearly 1 1/2 million annual diarrheal deaths globally. Methods: We followed 6-35 month old Nepalese children enrolled in the placebo-arm of a...

  • The role of rifaximin in the chemoprophylaxis of travelers' diarrhoea particularly aiming at the first 2 weeks of travel: a meta-analysis of 5 randomized, double-blind, controlled trials. Xiao Zheng; Wen Kang; Shanyu Guo; Huihui Liu // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 11, p20531 

    The role of rifaximin in travelers' diarrhoea (TD) patients remains effective in major researches and needs further exploration. We pursued one meta-analysis to evaluate the efficiency of rifaximin on TD patients. So a systematic search of integrant databases was performed to identify RCTs...

  • Saccharomyces boulardii for the Prevention of Antibiotic-Associated Diarrhea in Adult Hospitalized Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial. Pozzoni, Pietro; Riva, Alessia; Bellatorre, Alessandro Giacco; Amigoni, Maria; Redaelli, Elena; Ronchetti, Anna; Stefani, Mariangela; Tironi, Rosangela; Molteni, Edoardo Ennio; Conte, Dario; Casazza, Giovanni; Colli, Agostino // American Journal of Gastroenterology;Jun2012, Vol. 107 Issue 6, p922 

    OBJECTIVES:Antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD) are common complications of antibiotic use. Probiotics were effective in preventing AAD and CDAD in several randomized controlled trials. This study was aimed at testing the effect of...

  • A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. Chang, Lin; Ameen, Vanessa Z.; Dukes, George E.; McSorley, David J.; Carter, Eric G.; Mayer, Emeran A. // American Journal of Gastroenterology;Jan2005, Vol. 100 Issue 1, p115 

    BACKGROUND: A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS).METHODS: Six hundred and sixty-two men were randomized to treatment with alosetron 0.5, 1.0, 2.0, 4.0...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics